Abstract
Head and neck squamous cell carcinomas (HNSCC) are characterized by a marked propensity for local invasion and spread to cervical lymph nodes, with distant metastases developing in 30–40% of cases. HPV-16 is an important risk factor for HNSCC. How HPV enhances susceptibility to HNSCC is not fully understood, but seems to involve cofactors. In this study, we examined the effect of the cooperation between HPV-16 and the tyrosine kinase receptor ErbB-2 on E-cadherin/catenin complex patterns and neoplastic transformation of human normal oral epithelial (NOE) cells. We report that overexpression of ErbB-2 or E6/E7 alone does not affect E-cadherin/catenin complex patterns nor does it induce cell transformation of NOE cells. In contrast, coexpression of E6/E7 and ErbB-2 downregulates E-cadherin and catenin expression. This is accompanied by cytoplasmic localization of E-cadherin, as well as nuclear translocation of α, β, and γ-catenins. Furthermore, we demonstrate that E6/E7 cooperate with overexpressed ErbB-2 to induce tumor formation in nude mice and to upregulate cyclin D1 and c-myc expression. Our data suggest that E6/E7 cooperate with ErbB-2 in head and neck carcinogenesis, at least in part, via the conversion of β-catenin from a cell adhesion to a nuclear function, that is, to act as a potential transcriptional regulator. This conversion leads to the upregulation of cyclin D1, c-myc and other oncoproteins necessary for alteration of the E-cadherin/catenin complex and cell transformation of NOE cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Al Moustafa AE, Alaoui-Jamali MA, Batist G, Hernandez-Perez M, Serruya C, Alpert L, Black MJ, Sladek R and Foulkes WD . (2002a). Oncogene, 21, 2634–2640.
Al Moustafa A-E, Benlimame N, Yen L and Alaoui-Jamali MA . (2002b). Lung Cancer, 37, 49–56.
Al Moustafa AE, Yansouni C, Alaoui-Jamali MA and O'Connor-McCourt M . (1999). Clin. Cancer Res., 5, 681–686.
D'souza B and Taylor-Papadimitriou J . (1994). Proc. Natl. Acad. Sci. USA, 91, 7202–7206.
Dyson N, Guida P, Munger K and Harlow E . (1992). J. Virol., 66, 6893–6902.
Dyson N, Howley PM, Munger K and Harlow E . (1989). Science, 243, 934–937.
Eckert RL, Crish JF, Balasubramanian S and Rorke EA . (2000). Int. J. Oncol., 16, 853–870.
Forastiere A, Koch W, Trotti A and Sidransky D . (2001). N. Engl. J. Med., 345, 1890–1900.
Franceschi S, Munoz N, Bosch XF, Snijders PJ and Walboomers JM . (1996). Cancer Epidemiol. Biomarkers Prev., 5, 567–575.
Galipeau J, Li H, Paquin A, Sicilia F, Karpati G and Nalbantoglu J . (1999). Cancer Res., 59, 2384–2394.
Galloway DA and McDougall JK . (1996). Semin. Cancer Biol., 7, 309–315.
Gillison M, Koch WM and Shah KV . (1999). Curr. Opin. Oncol., 11, 191–199.
Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV and Sidransky D . (2000). J. Natl. Cancer Inst., 92, 709–720.
Gumbiner B, Stevenson B and Grimaldi A . (1988). J. Cell Biol., 107, 1575–1587.
Guy CT, Cardiff RD and Muller WJ . (1996). J. Biol. Chem., 271, 7673–7678.
Halbert CL, Demers GW and Galloway DA . (1991). J. Virol., 65, 473–478.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW . (1998). Science, 281, 1509–1512.
Ke LD, Adler-Storthz K, Mitchell MF, Clayman GL and Chen Z . (1999). Oral Oncol., 35, 415–420.
Klapper LN, Kirschbaum MH, Sela M and Yarden Y . (2000). Adv. Cancer Res., 77, 25–79.
Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines III GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ and Pestell RG . (2000). Mol. Cell. Biol., 20, 672–683.
Li B, Rosen JM, McMenamin-Balano J, Muller WJ and Perkins AS . (1997). Mol. Cell. Biol., 17, 3155–3163.
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG and Hung MC . (2000). Proc. Natl. Acad. Sci. USA, 97, 4262–4266.
McDougall JK . (1994). Curr. Top Microbiol. Immunol., 186, 101–119.
Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM . (2000). J. Clin. Oncol., 18, 1135–1149.
Ninomiya I, Endo Y, Fushida S, Sasagawa T, Miyashita T, Fujimura T, Nishimura G, Tani T, Hashimoto T, Yagi M, Shimizu K, Ohta T, Yonemura Y, Inoue M, Sasaki T and Miwa K . (2000). Int. J. Cancer, 85, 757–761.
Niv A, Sion-Vardi N, Gatot A, Nash M and Fliss DM . (2000). J. Laryngol. Otol., 114, 41–46.
Orford K, Crockett C, Jensen JP, Weissman AM and Byers SW . (1997). J. Biol. Chem., 272, 24735–24738.
Orr MS, O'Connor PM and Kohn KW . (2000). J. Natl. Cancer Inst., 92, 987–994.
Osborn L, Kunkel S and Nabel GJ . (1989). Proc Natl. Acad. Sci. USA, 86, 2336–2340.
Ozawa M, Baribault H and Kemler R . (1989). EMBO J., 8, 1711–1717.
Ozawa M and Kemler R . (1992). J. Cell Biol., 116, 989–996.
Rapp L and Chen JJ . (1998). Biochem. Biophys. Acta, 1378, F1–19.
Riese DJ and Stern FD . (1998). BioEssays, 20, 41–48.
Salomon D, Sacco PA, Roy SG, Simcha I, Johnson KR, Wheelock MJ and Ben-Ze'ev A . (1997). J. Cell Biol., 139, 1325–1335.
Scheffner M, Huibregtse JM, Vierstra RD and Howley PM . (1993). Cell, 75, 495–505.
Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA and Howley PM . (1994). Curr. Top. Microbiol. Immunol., 186, 83–99.
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R and Ben-Ze'ev A . (1999). Proc. Natl. Acad. Sci. USA, 96, 5522–5527.
Sidransky D . (1995). Curr. Opin. Oncol., 7, 229–233.
Takeichi M . (1990). Annu. Rev. Biochem., 59, 237–252.
Tzahar E and Yarden Y . (1998). Biochem. Biophys. Acta, 1377, M25–37.
Wilding J, Vousden KH, Soutter WP, McCrea PD, Del Buono R and Pignatelli M . (1996). Cancer Res., 56, 5285–5292.
Wong DT, Todd R, Tsuji T and Donoff RB . (1996). Crit. Rev. Oral Biol. Med., 7, 319–328.
Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL and Hung MC . (1999). Clin. Cancer Res., 5, 4164–4174.
Xie Y, Li K and Hung MC . (1995). Oncogene, 10, 2409–2413.
Yen L, Benlimame N, Zeng-Rong N, Xiao D, Wang T, Al Moustafa A-E, Esumi H, Hynes N, Milanini J, Pages G and Alaoui-Jamali AM . (2002). Mol. Biol. Cell, 13, 4029–4044.
Yu D and Hung MC . (2000). Oncogene, 19, 6115–6121.
Acknowledgements
We are grateful to Drs N Bachnou, D Hamilton, and M Loignon for critical reading of the manuscript. We also thank M Tong, C Serruya, and N Hamel for their technical assistance. This work was supported by the National Cancer Institute of Canada Grant # 010254 (WDF), the Canadian Genetic Diseases Network (WDF), the Fonds de la Recherche en Santé du Québec (FRSQ-Réseau du Cancer) (WDF, GB, LA, A-EA), and in part by Grant # 008491 and MT-14357 from the Canadian Breast Cancer Research Initiative and the Canadian Institutes for Health Research, respectively (MA-J).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Al Moustafa, AE., Foulkes, W., Benlimame, N. et al. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23, 350–358 (2004). https://doi.org/10.1038/sj.onc.1207148
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207148
Keywords
This article is cited by
-
High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study
Cancer Cell International (2021)
-
Co-presence of human papillomaviruses and Epstein–Barr virus is linked with advanced tumor stage: a tissue microarray study in head and neck cancer patients
Cancer Cell International (2020)
-
Co-prevalence of human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) in healthy blood donors from diverse nationalities in Qatar
Cancer Cell International (2020)
-
Electrospun polyvinyl alcohol membranes incorporated with green synthesized silver nanoparticles for wound dressing applications
Journal of Materials Science: Materials in Medicine (2018)
-
A muscle-specific protein ‘myoferlin’ modulates IL-6/STAT3 signaling by chaperoning activated STAT3 to nucleus
Oncogene (2017)